Launch Sale20% off everythingShop now
Research Use OnlyAll products are sold strictly for laboratory research — not for human consumption.

Metabolic & Fat Loss · Research Use Only

GLP-2 TZ

Also known as: Dual GIP/GLP-1 receptor agonist

GLP-2 TZ is a dual-incretin research peptide studied for agonism at both the GIP and GLP-1 receptors — the dual-agonist (tirzepatide-class) mechanism used in metabolic research.

View GLP-2 TZ product →

What is GLP-2 TZ?

GLP-2 TZ is our designation for a dual-incretin research peptide that acts as an agonist at two receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1. This dual-agonist approach is the tirzepatide-class mechanism studied in metabolic research.

How dual-incretin peptides are studied

In preclinical research, dual GIP/GLP-1 receptor agonists are investigated for how simultaneous activity at two incretin receptors affects signaling and metabolic markers in laboratory and animal models, compared with single-receptor agonists.

Handling, reconstitution & storage

Supplied lyophilized, stored at -20°C protected from light. Reconstituted with bacteriostatic or sterile water for research, then held at 4°C short-term or aliquoted at -80°C. An HPLC certificate of analysis accompanies each lot.

Frequently asked questions

  • What receptors does GLP-2 TZ act on?

    It is a dual agonist at the GIP and GLP-1 incretin receptors — the tirzepatide-class mechanism studied in metabolic research.

  • How does GLP-2 TZ differ from a GLP-1 agonist like Semaglutide?

    Semaglutide targets the GLP-1 receptor alone; GLP-2 TZ is a dual agonist that also targets the GIP receptor. Researchers compare single- vs multi-receptor agonism in metabolic models.

References

Related research peptides

Shop research-grade GLP-2 TZ, HPLC-tested with a COA on every batch.

View GLP-2 TZ

All information here is provided for laboratory and research reference only. Products are sold strictly for in-vitro research and development and are not for human or veterinary use.